Sol-Gel Technologies announces Health Canada approval of EPSOLAY

Sol-Gel Technologies (SLGL) announced that on August 27, 2025 Health Canada issued a Notice of Compliance, NOC, for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This approval comes as a result of Sol-Gel’s partnership with Searchlight Pharma, Sol-Gel’s exclusive licensee for commercializing EPSOLAY in the Canadian market. Under the exclusive license agreement signed in 2023, Searchlight was responsible for obtaining Canadian regulatory approval for EPSOLAY, and with this milestone achieved, Searchlight is preparing to launch EPSOLAY for rosacea patients in Canada. As part of the agreement, Sol-Gel is eligible to receive up to $11 million in combined potential upfront, regulatory and sales milestone payments for TWYNEO and EPSOLAY in Canada, in addition to tiered royalties on net sales. This non-dilutive revenue, alongside other partnerships, strengthens Sol-Gel’s balance sheet and supports the Company’s growth strategy.